All In Biotech

Drug Trial Radar · NCT02442427

"Palivizumab Therapy for RSV-bronchiolitis"

Treatment of Respiratory Syncytial Virus Bronchiolitis in Young Infants With Humanized Monoclonal Antibody: A Randomized Clinical Trial (Palivizumab Study)

Last checked: Nov 20, 2026Latest source record: Feb 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

420

Planned (sponsor's estimate)

Start

Sep 2014

Primary completion

Feb 1, 2018

Study completion Feb 1, 2018

Sponsor

Lead sponsor
Hamad Medical CorporationIndustry
Sponsor type
Industry
First posted
May 13, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, up to 3 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There is a growing body of literature suggesting that monoclonal antibody could be efficacious in infants with RSV-bronchiolitis, well tolerated with no or clinically insignificant adverse effects. "The investigators hypothesize that a single dose of iv palivizumab 15 mg/kg in diagnosed infants \<3 months old with RSV bronchiolitis will result in fewer infants with readmissions to infirmary/observation or hospital for relapse during 3 weeks of follow-up after discharge".

Conditions

  • Respiratory Syncytial Virus-bronchiolitis

Interventions

  • PalivizumabDrug

    A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.

  • PlaceboOther

    An equal volume of 0.9% normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Readmission to either infirmary/observation or hospital or PICU during 3 weeks of follow-up after dischargeTime frame: 3 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hamad Medical Corporation

    Doha, Qatar

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.